Remimazolam in obesity: weight drives clearance, sleep apnoea does not

Design

population pharmacokinetic study with stepwise escalating infusion and external validation, joint parent-metabolite model

Population

44 adult volunteers across a range of body weights, 30 (68.2%) with obstructive sleep apnoea

Primary outcome

remimazolam and CNS7054 pharmacokinetic parameters and covariate effects

Effect

clearance 1.09 l/min (RSE 4%), driven by total body weight; context-sensitive half-time 4.02 min after 4 h in class 2/3 obesity; no effect of apnoea severity

Forty-four adult volunteers, 30 of them with obstructive sleep apnoea, received stepwise escalating remimazolam infusions to deep sedation while arterial samples were drawn for a population pharmacokinetic model of the drug and its metabolite CNS7054. A three-compartment model fitted remimazolam best, and external validation held.

Two findings are useful at the bedside. Total body weight significantly affected clearance and the metabolite's volume of distribution, while no other covariate mattered — including the severity of obstructive sleep apnoea. And clearance was fast: after a four-hour infusion in class 2/3 obesity, context-sensitive half-time was 4.02 minutes. The modelling showed that dosing on lean or ideal body weight at induction, and on adjusted body weight for maintenance, gave exposure in class 2/3 obesity comparable to total body weight dosing in normal-weight patients.

Read this as a disposition study, not an outcome study. It tells you where the drug goes in a body of a given size; it says nothing about whether a patient with severe apnoea is more sensitive to a given concentration, and the authors flag that pharmacodynamics in this group remain untested. The reassurance is about the offset being predictable, not about airway risk being lower.

• Anchor induction on lean or ideal body weight, and maintenance on adjusted body weight, when using remimazolam in class 2/3 obesity
• Do not dose down for apnoea severity on pharmacokinetic grounds — it did not alter disposition
• Expect a short offset even after prolonged infusion; plan recovery monitoring on airway risk, not on drug persistence
• Volunteers under controlled infusion are not theatre patients with surgical stimulus and co-administered opioid
• Have flumazenil availability and reversal policy clear before relying on rapid offset in a difficult airway

The statistics, in plain English

Clearance of 1.09 l/min with a relative standard error of 4% means the model estimated this parameter tightly — the uncertainty is small relative to the value. A context-sensitive half-time of 4.02 minutes after four hours means accumulation is minimal, unlike drugs whose offset lengthens with infusion duration. Forty-four volunteers is a normal size for a pharmacokinetic model and an inadequate one for detecting uncommon adverse effects, which this study was not designed to find.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.